Patient Resource Publishing has assembled a prestigious Advisory Board to assist with editorial focus and ensure accuracy of the information presented. Members include well-known names from business and industry, opinion leaders from non-profit organizations, and highly respected medical doctors from the nation’s leading cancer treatment facilities. Editor-in-Chief is Charles M. Balch, MD, FACS, who oversees a team of seasoned medical writers to ensure editorial content is both accurate and engaging and presented with a sensitive professionalism meant to empower cancer patients and their families.

Medical Advisory Board:

Charles M. Balch, MD, FACS
Professor of Surgery, Oncology and Dermatology,
Johns Hopkins Medical Institutions
Editor-in-Chief, Patient Resource Publishing, LLC
Past President of the Society of Surgical Oncology

Click to Read More

Dr. Charles M. Balch leads a distinguished career as a clinical and academic surgical oncologist and a leading authority in both melanoma and breast cancer. As revered teacher, astute administrator, and world-renowned speaker, he continues to build networks in the field of clinical trials and outcomes research. Over the past 30 years he has authored over 600 publications on topics such as, clinical investigations involving staging and prognostic factors in melanoma, standards of surgical treatment in melanoma and breast cancer, and the conduct and methodology of clinical research and immunology. He is Chair of the Melanoma Staging Committee of the American Joint Committee on Cancer. Dr Balch is generally regarded as one of the leading melanoma experts in the world. He is the editor of Cutaneous Melanoma, regarded as the authoritative textbook on melanoma, now in its 5th edition. He is the founding Editor-in-Chief of the "Annals of Surgical Oncology" and "Breast Diseases" (emeritus). He also serves as Editor-in-Chief and on the Medical Advisory Board for the Patient Resource Cancer Guide.

Prior to coming to Johns Hopkins, Dr. Balch held major leadership roles involving clinical research in three comprehensive cancer centers (UAB, MD Anderson, and City of Hope). He has been a Principle Investigator or Co-PI of numerous clinical trials, most of which were NCI-funded National Phase III trials. He has organized or participated in randomized surgical trials that have defined the current standards of melanoma surgery. Dr. Balch's leadership roles have involved the Society of Surgical Oncology (President), the American Board of Surgery (Board of Directors), the Association of Academic Surgeons (President) and the Commission on Cancer (Chair, Board of Directors) and the American Joint Committee on Cancer (Executive Committee).

James Armitage, MD
Professor, Internal Medicine
Section of Hematology & Oncology
The Nebraska Medical Center University Hospital
Past President of the American Society of Clinical Oncology
Past President of the American Society of Bone Marrow Transplantation

Click to Read More

Dr. James O. Armitage is a graduate of the University of Nebraska Medical Center, completed his internship and residency in internal medicine at Nebraska, a fellowship in hematology oncology at the University of Iowa and a brief stint in private practice in Omaha. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska. He served as Vice-Chair of Internal Medicine, Chair of Internal Medicine, Dean of the College of Medicine and currently is The Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center. Dr. Armitage is board certified in internal medicine, medical oncology, and hematology, a Fellow of both the American and Royal College of Physicians, a past member of the National Cancer Advisory Board, past president of the American Society of Clinical Oncology and American Society of Blood and Marrow Transplantation. He is married and the father of four children and four grandchildren.

J. Max Austin, Jr., M.D.
Professor of Gynecologic Oncology
Department of Obstetrics and Gynecology
U.A.B. Medical Center
Past President of the Society of Gynecologic Oncologists

Click to Read More

As a young man, J. Max Austin, Jr., M.D. left his home town of Wetumpka, Alabama to attend Georgia’s Emory University. Four years and a bachelor’s degree later he came back to his home state, earning a medical degree at the Medical College of Alabama in 1967. Except for a year out of the state for residency training and two years in the Air Force, Austin has been in Alabama ever since.

Dr. Austin has practiced gynecologic oncology and taught residents and fellowship students in this state throughout his career. Indeed, the state of Alabama-and treating its female cancer patients-are very dear to his heart.

Austin did his first year of residency in Atlanta in 1968-69, then he finished his OB/GYN residency and fellowship in Alabama. Having progressed along the academic ladder, he is now a full professor at the UASOM. He also founded Southern Gynecology, a private practice in Birmingham, and practiced there 22 years.

When Austin returned to the UASOM in 2000, the University of Alabama Health Services Foundation and the Department of Obstetrics and Gynecology established the J. Max Austin, Jr., M.D. Professorship in Gynecologic Oncology in honor of his contributions to medicine and medical education in Alabama.

“There are some counties in Alabama that are equivalent to third-world countries in the death rates from cervical cancer, “he says. “This is tragic. We need to continue to educate, to teach the latest techniques in detection and diagnosis of gynecologic malignancies because many of them are potentially treatable if diagnosed early.”

Thomas A. Buchholz, M.D., FACR
Professor and Chair, Department of Radiation
The University of Texas M.D. Anderson Cancer Center
Frant T. McGraw Memorial Chair in the Study of Cancer

Click to Read More

Dr. Buchholz is professor and chair of the Department of Radiation at The University of Texas M. D. Anderson Cancer Center, Houston, Texas where he holds the Frank T. McGraw Memorial Chair in the Study of Cancer. Dr. Buchholz received his M.D. degree from Tufts University School of Medicine in Boston, MA and his postdoctoral residency and fellowship training at the University of Washington School of Medicine in Seattle, WA. His major clinical and research interest has been in the field of breast cancer radiation oncology.

Paul Bunn, MD
Executive Director, International Society for the Study of Lung Cancer
Past President of American Society of Clinical Oncology
Past Director, University of Colorado Cancer Center

Click to Read More

Education

Amherst College – 1967
Cornell University Medical Center
New York, NY – 1971

In 1984, Dr. Bunn was recruited to the University of Colorado Health Sciences Center as a Professor of Medicine in Medical Oncology and Head of the Division of Medical Oncology. In 1986 Dr. Bunn became the Director of the University of Colorado Comprehensive Cancer Center. Dr. Bunn has been President of ASCO, IASLC, and AACI, chairman of the FDA Oncology Drug Advisory Committee, and is currently the Executive Director of the IASLC.

Dr. Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, 122 reviews and 90 book chapters on lung cancer. Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct translational research.

Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA, Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18(4), 752-60, 2007.

Frederick B., Helfrich B., Coldren C.,. Zheng D., Chan D., Bunn P.A., Jr, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small-cell lung cancer. Mol Cancer Ther 6:(6), 2007.

University of Colorado Cancer Center Support Grant: NIH/NCI 4/4/97-1/31/11. $2,832,858 - 45% effort. The major goals are to contribute, through a coordinated research, clinical treatment, control and education effort to the eventual elimination of cancer as a human health problem and provide the citizens of the State of Colorado and the Rocky Mountain Region with state-of-the-art cancer therapy, research, control and education programs.

SPORE In Lung Cancer: NIH/NCI 09/30/1992 to 04/30/2013. $1,600,999 - 25% effort combined
The major goal of the overall project is to establish a Specialized Program in Research Excellence (SPORE) in Lung Cancer to expand our understanding of the biology of lung cancer, to find new methods of diagnosis, prevention and treatment and to serve as a regional, national and international resource for the study of lung cancer.

Frederick Greene, MD
Chair of Surgery, Carolinas Medical Center
Chair, Commission on Cancer

Click to Read More

Frederick L. Greene, MD, FACS, received his medical school training at the University of Virginia where he was elected to membership into AOA. He completed a residency in surgery at Yale University School of Medicine. Dr. Greene was also an American Cancer Society Clinical Research Fellow at Yale. He was on active duty with the United States Navy and was surgeon on the USS Nimitz. He is currently the Chairman of the Department of General Surgery at Carolinas Medical Center in Charlotte, North Carolina, Director of the Surgical Residency Program at that institution and Clinical Professor of Surgery at the University of North Carolina School of Medicine.

Dr. Greene is an active clinician in the area of surgical oncology and has been involved in organizational work pertaining to cancer for a number of years. Dr. Greene is a Fellow of the American College of Surgeons and has served on the Board of Governors of that organization. Dr. Greene serves on the Commission on Cancer of the American College of Surgeons and served as the Chair of the Commission from 2004-2008. He has represented the American College of Surgeons on the American Joint Committee on Cancer (AJCC) and served as Chair of the AJCC from 2000-2006. Dr. Greene is the Editor of the 6th Edition of the AJCC Cancer Staging Manual.

Dr. Greene belongs to numerous surgical organizations including the Society of Surgical Oncology, the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the Southern Surgical Association and the American Surgical Association. Dr. Greene was a founding member of SAGES and served as its president in 1992-93.

Dr. Greene's publications have included approximately 160 papers, 30 book chapters, and two textbooks relating to cancer surgery and, specifically, the use of laparoscopic surgery in the management of cancer patients. Dr. Greene serves as the Associate Editor of the Annals of Surgical Oncology and on numerous editorial boards including Surgical Endoscopy, Journal of Surgical Education, Journal of Surgical Oncology, World Journal of Surgery , American Surgeon, Journal of Clinical Oncology, Surgical Endoscopy, Laparoscopy and Percutaneous Techniques and is Editor of General Surgery News.

Jay R. Harris, MD
Professor and Chair
Department of Radiation Oncology
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Harvard Medical School
Past President, American Society for Radiology Oncology

Click to Read More

Dr. Harris is Professor and Chair of the Department of Radiation Oncology at The Dana-Farber Cancer Institute and the Brigham and Women's Hospital at Harvard Medical School. He also serves as Residency Program Director for the Harvard Radiation Oncology Residency Program.

Dr. Harris' main research interest has been in the area of breast cancer, with a focus on establishing the most effective and safe radiation treatment for these patients. He helped pioneer the use of breast-conserving therapy for patients with early stage breast cancer.

Dr. Harris has been an active member of several professional medical societies, including ASTRO where he served as President and Chairman of the Board of Directors and the American Board of Radiology where he served as Trustee.

Dr. Harris has published 100 articles and 150 peer-reviewed publications. He is the senior editor of Diseases of the Breast, now in its Fourth Edition.

Waun Ki Hong, MD
Chair of Medical Oncology,
MD Anderson Cancer Center
Past President of American Association for Cancer Research

Click to Read More

Waun Ki Hong, M.D., is a leading authority on head, neck and lung cancers and one of the founders of cancer chemoprevention. Dr. Hong is Head of the Division of Cancer Medicine and Professor of Medicine at the University of Texas M.D. Anderson Cancer Center in Houston. He is an American Cancer Society Professor and holds the Samsung Distinguished University Chair in Cancer Medicine.

Beginning in the early 1980’s, Dr. Hong’s organ preservation research established new treatment standards that have enormously improved the quality of life for advanced laryngeal cancer patients. His seminal chemoprevention research has clearly shown that high-dose retinoids can reverse oral carcinogenesis—a proof of principle that has led to a new paradigm for cancer chemoprevention. He continues an active research program in chemoprevention with multiple clinical trials, and his molecularly-targeted approaches have the potential to significant improve the morbidity and mortality of head/neck cancer and lung cancers. Dr. Hong’s research offers the possibility that cancer can be indefinitely delayed and possibly prevented, thus offering patients many more healthy years of life.

Dr. Hong is the recipient of numerous national and international awards including AACR’s Joseph A. Burchenal and Rosenthal Foundation Awards, ASCO’s David Karnofsky Award, and a prestigious American Cancer Society Clinical Research Professorship. He also served as president of AACR in 2001. More recently, he received the AACR/Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research and is currently an elected member of the ASCO Board of Directors.

In addition to his research and clinical work, Dr. Hong has played a pivotal role in shaping public policy. He was a member of the Advisory Committee to the Director of the NCI from 1997-2002 and chaired the Prevention, Clinical, and Therapeutic Subcommittee for the Extramural Board of Scientific Advisors (BSA) of the NCI from 1996-2002, and has served as an advisor for numerous other national organizations. He has trained and nurtured hundreds of young physicians and scientists from around the world, and has played an active role in increasing international collaborations in cancer research.

President George W. Bush appointed Dr. Hong to the National Cancer Advisory Board (NCAB) in 2008. Dr. Hong will serve a six-year term through March 9, 2014. The function of the NCAB is to advise, assist and make recommendations to the secretary of the Department of Health and Human Services and the director of the National Cancer Institute. The NCAB may also make recommendations regarding support grants and cooperative agreements, technical and scientific peer review, and functions pertaining to the NCI.

Gabriel N. Hortobagyi, M.D., F.A.C.P.
Professor of Medicine
Chairman, Dept. of Breast Medical Oncology The University of Texas M. D. Anderson Cancer Center
Past President of the American Society of Clinical Oncology

Click to Read More

Education
Universidad Nat’l of Columbia, M.D. Degree in Medicine, 1970.
St. Luke’s Hospital, Cleveland, OH, Resident Internal Medicine, 1971-74
U.T. M.D. Anderson Hospital, Houston, TX, Fellow Medical Oncology, 1976A. Positions and Honors Positions and Employment

Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, and Champlin RE: Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. J Natl Cancer Inst 92(3):225-233, 2000.

Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Warner DL, Payne JY, Tucker SD, Bartolomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC: Cationic Liposome-Mediated Adenovirus Type 5 E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biological Effects: A Phase I Clinical Trial. J Clin Oncol 19:3422-3433, 2001.

Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer HM, Buchholz TA, and Hortobagyi GN: Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. J Clin Oncol 23(1):41-48, 2004.

Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN: Significantly Higher Pathological Complete Remission Rate After Neoadjuvant Therapy with Trastuzumab, Paclitaxel and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. J Clin Oncol 23(16):3676-3685, 2005

Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M: Biologic Markers in Axillary Node-Negative Breast Cancer: Differential Expression in Invasive Ductal Carcinoma versus Invasive Lobular Carcinoma. Clin Breast Cancer 7(5):396-400, 2006.

Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, and Hortobagyi GN: Neoadjuvant Therapy with Paclitaxel Followed by 5-Fuorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clin Cancer Res 13(1):228-233, 2007.

Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M: Kinetics of Serum HER-2/neu Changes in Patients with HER-2-Positive Primary Breast Cancer After Initiation of Primary Chemotherapy. Cancer 109(3):496-501, 2007. [Epub ahead of print on December 5, 2006].

Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN: Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients with Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. J Clin Oncol 2007. [Epub ahead of print on July 2, 2007].

Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G: Mammography Before Diagnosis Among Women Age 80 and Older with Breast Cancer. J Clin Oncol 2008. [Epub ahead of print on April 21, 2008] PMID: 18427152

Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS: Limits of Observational Data in Determining Outcomes from Cancer Therapy. Cancer 2008. [Epub ahead of print on April 21, 2008] PMID: 18428196

Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF and Hortobagyi GN: The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw in Cancer Patients Treated with Intravenous Bisphosphonates. J Bone Min Res 2008. [Epub ahead of print on February 5, 2008] PMID: 18435574

Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA: Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys 2008. [Epub ahead of print on April 24, 2008] PMID: 18439768

Srokowski TP, Fang S, Duan Z, Buchholz TA, Hortobagyi GN, Goodwin JS, Giordano SH: Completion of Adjuvant Radiation Therapy Among Women With Breast Cancer. Cancer 2008. [Epub ahead of print on April 28, 2008] PMID: 18442124

Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans FW and Pusztai L: Evaluation of Biological Pathways Involved in Chemotherapy Response in Breast Cancer. Breast Cancer Res 2008. [Epub ahead of print on April 29, 2008] PMID: 18445275

Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM; for the Inflammatory Breast Cancer Research Group: Prognostic Significance of HER-2 Status in Women with Inflammatory Breast Cancer. Cancer 112(9):1905-1911, 2008. [Epub ahead of print February 25, 2008]. PMID: 18300243

1 P50 CA116199-01 Hortobagyi (PI)
9/23/2005 – 8/31/2010
NIH/NCI - UTMDACC SPORE in Breast Cancer
The goal of this project is to foster interactive, multi-specialty translational research in breast cancer diagnosis, prevention and treatment.
Role: PI

2P30 CA016672 28(PP-4) Hortobagyi (PI)
7/1/2003-6/30/2013
DHHS-NIH-NCI
Cancer Center Support (Core) Grant-Project 4-Breast Cancer Program
The major goal of this project is to establish the research infrastructure and organization for the Breast Cancer Research Program at The University of Texas M. D. Anderson Cancer Center.
Role: PI

Susan G. Komen Breast Cancer Foundation
7/1/2002 – 6/30/2010
Interdisciplinary Breast Cancer Fellowship Program
Hortobagyi (Program Director)
The major goal of this grant is to provide interdisciplinary training to physicians specializing in all aspects of the management of breast diseases.
Role: Program Director

ASCO Career Development Award Gonzalez-Angulo (PI)
7/1/2006 - 6/30/2009
The PI3K/PTEN/AKT Signal Transduction Cascade as a Predictor for Response to Therapy and Therapeutic Target in Breast Cancer
Goal: To study the role of the PI3K/PTEN/AKT Signal Transduction Cascade in breast cancer as a classifier, predictor of response, and target for preoperative therapy.
Role: Mentor

NCI: 1 U10 CA105409 Lippman (PI)
U10 Full Member Application Affiliated with SWOG
7/26/04-12/31/09
Goal: Development of Studies
Role: Co-Investigator

NCI: DHHS-NIH: 1 K23 CA12199401 (Gonzalez-Angulo (PI)
The PI3K/PTEN/AKT Signal Transduction Cascade in Breast Cancer
7/1/06-6/30/11
Goal: To study the relationship of P13K, PTEN, and SKT signal transduction in breast cancer.
Role: Consultant

The Breast Cancer Research Foundation: Breast Cancer-Targeted Therapy by Endostatin-Cytosine Deaminase Fusion Protein. (G.N. Hortobagyi, PI)
10/1/2008 – 9/30/2009
Role: PI

DHHS–NIH-National Cancer Institute: 3 P50 CA116199-02S1 Bondy (Project PI)
(SPORE Supplement)
9/28/06 – 8/31/2008
Comparative Study of Breast Cancers and their Risk Factors Among Mexican Women in Mexico and the U.S.
Goal: Study the difference of risk factors between Mexican American women in the US and Mexico.
Role: SPORE PI

Entertainment Industry Foundation: EIF/WCRF Breast Cancer Biomarker Discovery Project.
P.I.: Leyland Hartwell
10/5/07 – 10/4/08
Role: Steering Committee Member: October 5, 2007 through October 4, 2008.

NCI: DHHS-NIH (1 K01 CA118174 01) Nahta (PI)
HER-2/IGF-1R Crosstalk and Herceptin Resistance
8/1/06 – 2/15/08
Goal: Study the relationship of HER-2/IGF-1R and Herceptin Resistance.
Role: Investigator

DAMD17-02-1-0694 01 Hortobagyi (PI)
9/1/2002 – 8/31/2007
USAMRMC-DOD Breast Cancer Research Program
Breast Cancer Center of Excellence: Development of Targeted Therapy Strategies for Breast Cancer.
The major goals of this project are to develop an interactive, multidisciplinary center that will combine expertise in molecular biology, novel animal models and clinical trials expertise to expedite the discovery and development of novel targeted therapies.
Role: PI

DAMD17-02-1-0456 1 Pusztai (PI)
4/012002 –4/31/2006
USAMRMC “The Role of Sigma Receptor in Breast Cancer”
The major role of this grant is to study and discover the role of sigma receptors in breast cancer.
Role: Co-Investigator

1RO1CA89608-O1A1 Bondy (PI)
7/1/2000 – 6/30/2006
NCI
Epidemiologic and Genetic Determinants of Breast Cancer Survival
The major goals of this project are to understand the influence of genetic and environmental influences on survival of patients with breast cancer.
Role: Co-Investigator

LaSalle D. Leffall, Jr., M.D.,FACS
Professor and Chairman, Department of Surgery, Howard University
Chair of the Susan G. Komen for the Cure and the President's Cancer Panel
Past President of the American Cancer Society, Society of Surgical Oncology, American College of Surgeons, Society of Surgical Chairmen and Society of Black American Surgeons.

Click to Read More

Dr. LaSalle D. Leffall Jr., is one of the leading authorities in breast cancer. He served as Chair of the Susan G Komen for the Cure organization and is past president of the American Cancer Society, Society of Surgical Oncology, American College of Surgeons, Society of Surgical Chairmen and Society of Black Academic Surgeons. Currently, he is Chair of the President’s Cancer Panel (for President Obama) and of C-Change (Along with former President George H. W. Bush). He was Professor and Chairman, Department of Surgery at Howard University for 25 years.

Larry Norton, MD
Deputy Director for Breast Oncology,
Memorial Sloan Kettering Cancer Center
Past President of American Society of Clinical Oncology

Click to Read More

Larry Norton, M.D is Deputy Physician-in-Chief and Director of Breast Cancer Programs at Memorial Sloan-Kettering Cancer Center. He is Scientific Director of The Breast Cancer Research Foundation (BCRF), and has served as chairman of the BCRF Medical Advisory Board since its inception in 1993. Dr Norton is Past President of the American Society of Clinical Oncology, and Chair of the ASCO Foundation. A Presidential Appointee to the National Cancer Advisory Board of the NCI (1998-2004), he is the first incumbent of the Norna S. Sarofim Chair in Clinical Oncology at MSKCC and recipient of the American Society of Clinical Oncology’s 2004 David A. Karnofsky Memorial Award.

After receiving his M.D. from the College of Physicians and Surgeons, Columbia University, he trained in Internal Medicine at the Albert Einstein College of Medicine. He then served as a Clinical Associate and Investigator at the NCI prior to joining the faculty of the Mount Sinai Medical Center in New York from 1977-1988. He is currently Professor of Medicine, Weill Medical College of Cornell University.

Dr. Norton has served on or chaired numerous committees of governmental and professional organizations, including the NCI's Cancer Clinical Investigations Review Committee, its Cooperative Breast Cancer Tissue Resource (Registry), and the Consensus Development Conference on Treatment of Early Stage Breast Cancer (1990). He has also served on several committees of the Institute of Medicine of the National Academy of Sciences. Dr. Norton is on the editorial board of several medical publications, and is an active clinical and laboratory investigator. He is the co-author of the Norton-Simon Model, which has broadly influenced cancer treatment and research for over twenty-five years.

Dr. Norton has received numerous honorary visiting professorships including the Belsky-Moranis Memorial Lectureship, New York University Medical Center; the Shoshana Biran Visiting Professorship, Hadassah University Hospital, Jerusalem; the Schlager Visiting Professorship, Dana-Farber Cancer Institute; the Vivian Saykaly Visiting Professorship, McGill University and Université de Montreal 2003; and the Paul Carbone Visiting Professorship, University of Wisconsin Comprehensive Cancer Center, The William L. McGwire Lecture.

He has also been honored by many organizations including Y-ME National Breast Cancer Organization, the American-Italian Foundation for Cancer Research, the Don Shula Foundation, NABCO, Cancer Care, Share (NY), and the Susan G. Komen Foundation.

Nicholas Petrelli, MD
Medical Director, Helen F. Graham Cancer Center
President of Society of Surgical Oncology

Click to Read More

Nicholas Petrelli, M.D. is Professor of Surgery in the Department of Surgery at Thomas Jefferson University and Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center at Christiana Care, Newark, Delaware.

Dr. Petrelli has been active on numerous advisory panels, including the American Society of Clinical Oncology Expert Panel on Colorectal Cancer Surveillance and the National Cancer Institute Colorectal Cancer Consensus Working Group. He is an active member of a number of professional organizations, including the Society of University Surgeons, the American Surgical Association, the American Society of Clinical Oncology, and the Society of Surgical Oncology. He is the past President of the Society of Surgical Oncology. He presently is Chair of the Colorectal Committee of the National Surgical Adjuvant Breast and Bowel Project (NSABP).

Dr. Petrelli has been the author of 293 manuscripts in peer reviewed journals. He is an Associate Editor for the Journal of Clinical Oncology and Editor of the Surgical Oncology Clinics of North America. He also is a member of the editorial boards of the journals Cancer Chemotherapy and Pharmacology and Surgical Oncology.

Dr.Petrelli earned his undergraduate degree from the University of Notre Dame in 1969 and his medical degree from Tulane Medical School in 1973. He completed his general surgery residency in San Francisco in 1978 and post doctoral training in surgical oncology at the Roswell Park Cancer Institute in 1980. He spent the ensuing 21 years at the Roswell Park Cancer Institute during which time he was appointed Chair of the Division of Surgical Oncology and Director of the Surgical Oncology Fellowship Program from 1991 to 2001.

He has been married to his wife Cathy for 30 years and they have 2 children, Nicole a junior at Hilbert College in Buffalo, NY and Gabriella, a senior in high school. Nicole is interested in forensic science and Gabriella in marine biology. Dr Petrelli continues to enjoy Delaware beach time with his family and the rich history of the Delaware Valley. He has family in the New York City area with makes it convenient for spur of the moment visits. He also has two nephews, Doug and Justin, who keep him young at heart with visits to mid town Manhattan.

Raphael Pollock, MD
Chair of Surgery, MD Anderson Cancer Center
Past President of the Society of Surgical Oncology

Click to Read More

Dr. Raphael Pollock, MD, PhD was born in Chicago, IL where he received his primary and secondary school education. Dr. Pollock graduated from Oberlin College in 1972 with a BA in History (high honors). He received his MD degree from St. Louis University, St. Louis, Missouri and then completed residency training in General Surgery at the University of Chicago and Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL. This was followed by a fellowship in Surgical Oncology at the University of Texas M. D. Anderson Cancer Center, Houston, TX. Upon completion of fellowship training in 1984, Dr. Pollock joined the faculty in the Department of Surgical Oncology at The University of Texas. He completed PhD training at the Graduate School of the Biological Sciences, University of Texas Health Sciences Center / Houston in 1990, and was promoted to Associate Professor the following year. Dr. Pollock became Chairman of the Department of Surgical Oncology in 1993, was promoted to Professor in 1995, and became Head of the Division of Surgery at The University of Texas M. D. Anderson Cancer Center in 1997.

Dr. Pollock has a lifetime professional dedication to patient care and research in soft tissue sarcoma. His clinical practice focuses exclusively on this disease entity, and he has pursued clinical and laboratory research interests in soft tissue sarcoma during the entire time that he has been a member of the faculty of the Department of Surgical Oncology. Currently Dr. Pollock provides leadership for the Sarcoma Research Center at The University of Texas M. D. Anderson Cancer Center. His laboratory research interests include molecular-oriented tissue- and cell line-based investigations focusing on the role of the p53 tumor suppressor gene in soft tissue sarcoma, modulation of angiogenesis in soft tissue sarcoma, mechanisms of soft tissue sarcoma chemoresistance, as well as the development of novel therapeutics for this disease. Dr. Pollock is the incumbent in the Senator A.M. Aiken, Jr., Distinguished Chair, and holds joint appointments in the Department of Molecular and Cellular Oncology at The University of Texas M. D. Anderson Cancer and the Department of Surgery at The University of Texas Health Sciences Center/ Houston.

Richard Reiling, MD
Medical Director, Presbyterian Cancer Center
President of Association of Community Cancer Centers

Click to Read More

Richard Reiling is a native of Dayton, Ohio and received his undergraduate education at the University of Dayton. In the interim between undergraduate studies and medical school, he was a high school teacher, the beginning of a life-long avocation for teaching. After graduating from Harvard Medical School he completed training in surgery at Harvard and an oncology Fellowship at the Lahey Clinic.. He served in the USAF during the Vietnam conflict era. Dr. Reiling entered private practice in his hometown at the same time that a new medical school was being formed in Dayton. He became a charter faculty member at Wright State University School of Medicine and remains on that faculty throughout his career. Currently, Richard is a Clinical Professor of Surgery at Wright State.

Dr Reiling’s personal interest has always been in the care of patients with cancer, especially those with breast cancer. He was instrumental in developing a cancer program at his main hospital, Kettering Medical Center, named after the inventor Charles F. Kettering and located on the lawns of the former Kettering estate. The hospital was shortly thereafter recognized by US News and World Report as one of the nation’s top 50 hospitals for cancer care. During this time he continued a very active practice as well as a busy teaching schedule.

In the summer of 2000, he was recruited by Ohio Health’s flagship hospitals in Columbus, Ohio as the VP for Cancer Services. During the next several years, Dr. Reiling provided the support and leadership to bring that institution’s cancer program to a high level of recognition in a community that already had a major cancer hospital as part of Ohio State University.

He found an offer to a similar position as the Medical Director of the Presbyterian Cancer Center too good to not accept. The position at Presbyterian and the beauty of the city was enough for the Reilings to give their Ohio roots and move to the Carolinas.

Dr. Reiling has worked diligently to develop programs that improve the care of patients with cancer. In addition to breast cancer, he is especially active in lung cancer. It is in this situation that he has a very strong interest in the prevention of lung cancer and other respiratory diseases related to cigarette smoke. He has served with SmokeFree Mecklenburg for several years and often speaks and writes about the hazards of second-hand smoke.

Dr. Reiling has served on many professional society boards and committees, including the President of the Ohio Chapter of the American College of Surgeons and a Governor of the American College of Surgeons. Currently, he is the Second VP-Elect of the American College of Surgeons. In addition, he has served on many community and church organizations including the United Way, and the Dayton Opera Association. In his spare time, he was able to be a Boy Scout Master for a troop in Kettering Ohio, and proudly lists many young men who became Eagle Scouts during his tenure. Currently he serves on the Mecklenburg Council of the Boys Scouts of America, along with other civic boards. He is a member of the Charlotte Rotary Club.

Dr. Reiling is married to his childhood sweetheart, Liz, and celebrated their 44th anniversary this June. The Reilings have two grown children, Maureen DeBlois, a senior hospital executive in Atlanta, and Richard B. Reiling Jr., an attorney in Boston. The Reiling’s have 3 grandchildren. Richard enjoys golf, skiing, and just being involved.

Richard Schilsky , MD
Professor of Medicine, University of Chicago Medical Center
Chairman, Cancer and Leukemia Group Cooperative Group
President of the American Society of Clinical Oncology

Click to Read More

Dr. Schilsky earned his M.D. at the University of Chicago Pritzker School of Medicine in 1975. Following a residency in Internal Medicine at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital, he received training in Medical Oncology and Clinical Pharmacology at the National Cancer Institute from 1977 to 1981. He then served as Assistant Professor of Medicine at the University of Missouri-Columbia School of Medicine from 1981-1984 when he returned to the University of Chicago. At the University of Chicago, he served as Director of the Cancer Research Center from 1991-1999 and as Associate Dean for Clinical Research from 1999-2007. Since 1995, Dr. Schilsky has also served as Chairman of the Cancer and Leukemia Group B, an NCI-funded cooperative group.

An international expert in gastrointestinal malignancies and cancer pharmacology, he has served on a number of peer review and advisory committees for the NCI and the FDA. He has served as a member and Chair of the Oncologic Drugs Advisory Committee for the FDA, and presently serves as a member of the NCI Board of Scientific Advisors and the NCI Clinical Trials Advisory Committee. He is a former member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and currently serves as ASCO President 2008-2009.

He is a member of the external advisory committees of several comprehensive cancer centers including the Roswell Park Cancer Institute, the Mayo Cancer Center, the MD Anderson Cancer Center, the Fred Hutchinson Cancer Research Center, the University of California at San Francisco Comprehensive Cancer Center and the Simmons Cancer Center at UT-Southwestern.

Dr. Schilsky is an Associate Editor of Clinical Cancer Research and a member of the editorial board of Seminars in Oncology and the Journal of Cancer Research and Clinical Oncology. He has published more than 250 articles and book chapters in the medical literature and has edited 4 books.

Donald L. Trump, MD, FACP
President and CEO
Roswell Park Cancer Institute

Click to Read More

Dr. Donald L. Trump was appointed President and Chief Executive Officer of Roswell Park Cancer Institute (RPCI) on April 1, 2007. Since coming to RPCI in January 2002, Dr. Trump has served as Senior Vice President for Clinical Research; Chair, Department of Medicine; and Co-Principal Investigator of the Cancer Center Support Grant (CCSG) funded by the National Cancer Institute. In the fall of 2006, he was appointed Associate Institute Director.

As RPCI President & CEO and Principal Investigator of the CCSG, Dr. Trump has direct authority over day-to-day operations, philanthropic and operating budgets, capital improvements, research priorities and clinical and scientific strategic planning for the Institute. He is responsible for establishing a culture of excellence throughout RPCI’s key mission areas: research, clinical care, education and cancer prevention.

In addition to his role as President and CEO, Dr. Trump continues his work as a researcher and clinician, leading the Institute’s active clinical research in vitamin D-based cancer prevention and treatment, and caring for patients with prostate cancer and other urologic cancers. He also will continue as principal investigator or co-principal investigator on several grants funded by the National Cancer Institute and Department of Defense. He holds European and U.S. patents for the use of vitamin D and vitamin D analogs in combination with high-dose chemotherapy.

Dr. Trump earned his medical degree from The Johns Hopkins University School of Medicine, Baltimore, MD, in 1970. From 1970 to 1975, he completed an internship and residency training in Medicine and a fellowship in Oncology and served as Chief Resident in Internal Medicine at The Johns Hopkins Hospital. Dr. Trump is a Diplomate of the American Board of Internal Medicine, with Subspecialty Boards in Medical Oncology, and a Fellow of the American College of Physicians. Dr. Trump is past Secretary/Treasurer of the American Society of Clinical Oncology, and is a member of many professional and scientific societies. He is a reviewer and/or member of the editorial board of prestigious journals, such as the New England Journal of Medicine, Journal of National Cancer Institute, Cance, Journal of Urologic Oncology, Clinical Cancer Research, Cure, Oncology, American Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Cancer Research, and Journal of Clinical Oncology. Dr. Trump has authored or co-authored more than 200 journal publications, book chapters and abstracts.

David Winchester, MD
Director of Cancer Department,
American College of Surgeons
Chair Emeritus, Department of Surgery,
Evanston Northwestern Medical Center
Past President of Society of Surgical Oncology

Click to Read More

Dr. Winchester graduated from Northwestern University and received his general surgical training at Northwestern. He completed his surgical oncology fellowship at M.D. Anderson Cancer Center. He is currently Professor of Surgery at Northwestern University, Feinberg School of Medicine and the immediate past Chairman of the Department of Surgery of Evanston Northwestern Healthcare. He is the Medical Director of the National Cancer Programs of the American College of Surgeons and Principal Investigator of the National Cancer Database (NCDB) with a focus on tracking outcomes in cancer patients and promoting continuous quality improvement of cancer care. Dr. Winchester has authored 184 peer-reviewed journal articles, serves on 10 editorial boards and has edited/co-edited 5 books. He is a past-president of the Society of Surgical Oncology and currently serves as the Executive Director of the American Joint Committee on Cancer. He is the Chairman of the National Accreditation Program of Breast Centers (NAPBC) for the American College of Surgeons. He is an honorary member of the American Society for Therapeutic Radiology and Oncology and an honorary fellow of the American College of Radiology.

Patient Advisory Board:

Alan Balch
Vice President, Preventive Health Partnership
American Cancer Society
American Diabetes Association
American Heart Association

Click to Read More

Dr. Alan Balch is Vice President of the Preventive Health Partnership, a collaboration between the American Cancer Society, the American Diabetes Association, and the American Heart Association. He is the past Executive Director of Friends of Cancer Research. Dr. Balch volunteers as a member of the Board of Directors for the Center for a New American Dream, the Colorectal Cancer Coalition, and the Patient Advocate Foundation. He holds a doctorate in Environmental Studies and a master’s in Environmental Sciences.

Diane Blum, MSW
CEO of the Lymphoma Research Foundation
Editor-in-Chief, ASCO's Cancer.Net

Click to Read More

Diane S. Blum is Chief Executive Officer of the Lymphoma Research Foundation, the nation's largest voluntary health organization devoted exclusively to funding lymphoma research and providing patients and health care professionals with critical information on the disease. She also served for twenty years as the Executive Director of CancerCare and continues to serve as Editor-in-Chief of ASCO’s cancer.net. Ms. Blum is a founder of National Breast Cancer Awareness Month and Co founder of the National Alliance of Breast Cancer Organizations. Most recently, she received ASCO's 2009 Partners in Progress award which honors patient advocates whose work has increased public awareness about cancer and its causes, cures and treatment.

Peggy Conlon
President and CEO, Ad Council

Click to Read More

As President & Chief Executive Officer of The Advertising Council, Peggy Conlonmobilizes the creative services of over 50 major advertising agencies, and related financial support from hundreds of corporations to produce $2 billion a year in Public Service Announcements. Ms. Conlon serves on the Board of Trustees of the United Way of America, and on the LPGA Commissioner's Advisory Council. Ms. Conlon has also been appointed by former President George H. W. Bush and Barbara Bush to lead the national media initiative for C-Change, formerly the National Dialogue on Cancer.

Nancy Davenport-Ennis
Founder and CEO,
National Patient Advocate Foundaion and
Patient Advocate Foundation

Click to Read More

Nancy Davenport-Ennis, cancer survivor, is the Founder and Chief Executive Officer of National Patient Advocate Foundation and the Patient Advocate Foundation. She was appointed by the United States Secretary of Health and Human Services as a Commissioner on the American Health Information Community. Most recently, Ms. Davenport-Ennis was elected by the membership of the National eHealth Collaborative (NeHC) in 2010 to serve as designated consumer representative on the NeHC Board of Directors. She has received numerous awards, among them the U.S. Oncology Medal of Honor Award and the 2005 Women in Business Achievement Award presented by Anthem and Business Week. In 2008, she was selected by Yoplait and Susan G. Komen for the Cure as a Yoplait Champion for selflessly fighting breast cancer.

Sam Donaldson
ABC Newscaster

Click to Read More

Sam Donaldson is an internationally known broadcast journalist and a 42-year veteran of ABC News for whom he served two appointments as chief White House correspondent covering Presidents Carter, Reagan and Clinton. In 1998 Mr. Donaldson received the prestigious Broadcaster of the Year Award from the National Press Foundation. The Washington Journalism Review named him the Best Television Correspondent in the Business in 1986, 1987, 1988 and 1989. Mr. Donaldson has won many other awards, among them four Emmy Awards and three Peabody Awards. His 1987 autobiography, "Hold On, Mr. President," was an international bestseller. Currently, Mr. Donaldson is appearing on ABC News Now, the ABC News digital network.

Lisa Greaves
Publisher, American Society of Clinical Oncology

Click to Read More

Lisa Greaves is the Director of Integrated Media at the American Society of Clinical Oncology. She is a 14-year survivor of breast cancer who connects with newly diagnosed patients through organizations in her community. Lisa has been a speaker at the American Cancer Society’s Making Strides Against Breast Cancer event, a participant in clinical trials through the Cancer Genetics Network at Georgetown University Hospital, and an interviewee for a MacNeil-Lehrer NewsHour program on BRCA-1 mutations. She is a graduate of the National Breast Cancer Coalition Fund’s Project LEAD Institute. Lisa has explored her own cancer journey through photography and poetry.

Linda House, RN, BSN, MSM
Director of Advocacy & Professional Relations, US Affiliate
Eli Lilly and Company

Click to Read More

Linda House is currently the Director of Advocacy and Professional Relations for the U.S Affiliate of Lilly USA, LLC which includes outreach across a number of therapeutic areas including diabetes, mental health, oncology, women’s health, cardiovascular, and acute care. She has led the company’s Oncology Patient and Professional Outreach program since 2000. She serves on the Board of Directors of the Breast Cancer Network of Strength. Prior to joining Lilly, Ms. House had a rich history as an oncology nurse. She initiated the Peripherally Inserted Central Catheter (PICC) program in her facility and subsequently, multiple facilities across the state of Indiana.

Lillie Shockney, RN., BS., MAS
University Distinguished Service Assistant Professor of Breast Cancer
Administrative Director, Johns Hopkins Avon Foundation Breast Center
Assistant Professor, Departments of Surgery and Gynecology, JHU School of Medicine

Click to Read More

Lillie D. Shockney, is an active clinical researcher with a focus on quality of life issues for survivors. She has written eight books and many articles on the subject of breast cancer. She is the co-founder and vice president of "Mothers Supporting Daughters with Breast Cancer." She serves as Ask an Expert for several breast cancer Websites including Yahoo.com and the Johns Hopkins Breast Center's Website. She chairs the National Consortium of Breast Centers QI Task Force.

Doug Ulman
President, Lance Armstrong Foundation

Click to Read More

Doug Ulman is a three-time cancer survivor and national cancer survivorship advocate. In 1997 he founded the Ulman Cancer Fund for Young Adults, a non-profit organization to provide support, education and resources to young adults, their families and friends who are affected by cancer. In addition to his work as President and Chief Executive Officer the Lance Armstrong Foundation, Mr. Ulmanserves as chairman of the National Cancer Institute Director’s Consumer Liaison Group and sits on the Google Health Advisory Board. He is a member of the American Society of Clinical Oncology and co-founder of the LIVESTRONG™ Young Adult Alliance.

Louise Villejo
Executive Director for Patient Education
MD Anderson Cancer Center

Click to Read More

Louise Villejo is Executive Director of the Patient Education Office at the University of Texas M. D. Anderson Cancer Center in Houston. She has been responsible for the development, implementation and evaluation of strategic, financial and operational plans for hospital and clinic-based patient education services for over 27 years. These services include development of relevant educational programs in each clinical area including a comprehensive array of electronic, print, audiovisual and computer-based educational resources and Patient/Family Learning Centers. Ms. Villejo provides leadership to assure the integral role of patient/family education programs within institutional strategic initiatives and meeting accreditation standards.

Armin Weinberg, PhD
Co-Founder, Intercultural Cancer Council

Click to Read More

Dr. Armin D. Weinberg has been the Director of the Chronic Disease Prevention and Control Research Centersince its inception in 1987 as the Center for Cancer Control Research. Dr. Weinberg is the Principal Investigator of the project Eliminating Disparities in Clinical Trials (EDICT), launched in 2005. Recognizing that medically underserved populations have the lowest rates of participation in clinical trials, the EDICT initiative is designed to address the problems and find workable solutions to recruiting and retaining populations that are underrepresented in clinical trials such as low income, elderly, racial-ethnic minorities or those who live in rural areas.